Definitive Contract 75N91023C00047

Award Date 8/31/23
Potential Completion Date 11/30/24
Potential Value $455K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Los Altos, CA 94024, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
6
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Phenomapper, LLC, a minority-owned, self-certified small disadvantaged business located in San Jose, California. The $398,952.00 firm-fixed-price contract was awarded on September 16, 2020, with a completion date of September 15, 2021. The contract is for the development of artificial intelligence-aided imaging technology...
This $399,987 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Care Progress LLC, a small business limited liability company. The contract supports the development of cancer clinical trials recruitment and retention tools for participant engagement, as described in the original SBIR solicitation. The solicitation sought proposals for SBIR Phase I and Phase II contracts to conduct...
This is a $289,828.00 SBIR Phase I contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Nicolalde R&D LLC, a minority-owned, self-certified small disadvantaged business. The contract is a firm fixed-price definitive contract with a completion date of November 30, 2021. The SBIR (Small Business Innovation Research) Program Phase I award indicates this contract is for early-stage research and development activities. As a...
This is a $399,992 firm fixed price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Xanthoshealth, Inc., a small business concern, to develop "Software to Address Social Determinants of Health in Oncology Practices" under the NCI's SBIR program. The original solicitation sought proposals for innovative research across various biomedical and public health topics, including digital health tools, to contribute towards the NCI and Centers for Disease Control and...
This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
This is a $455,000 firm fixed price contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS). The contract was awarded to Mrimath LLC, a small disadvantaged, woman-owned limited liability company, for a Small Business Innovation Research (SBIR) Phase I project related to Artificial Intelligence-aided imaging for cancer prevention, diagnosis, and monitoring. The contract has a...
This SBIR Phase I contract from the National Cancer Institute, valued at $361,254, was awarded to Avident Health LLC. The firm will develop its MyNavigator mHealth application for use in patient navigator breast cancer care workflows, as requested under NIH Solicitation 406. This total small business set-aside solicitation sought proposals for Phase I and Phase II SBIR contracts to conduct R&D supporting NIH and CDC agency missions, including alternatives to cell culture materials and cancer...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS). The $225,000 Firm Fixed Price contract was awarded to Dimagi Inc., a self-certified small disadvantaged business, to develop a digital health solution to support long-term cancer survivorship using patient navigation. The contract is part of the NCI Cancer Moonshot program. Dimagi...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $453,123 Small Business Innovation Research (SBIR) Phase I contract to Pistevo Decision LLC, a minority-owned small business, to develop an integrated multi-level decision support platform to address patient-centered and evidence-based social determinants of health among cancer patients. This Phase I contract is part of a two-year $2 million SBIR Phase II award granted to Pistevo in September 2023....
This is a $399,870 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Apricity Health LLC, a small business based in Houston, Texas. The contract is for the development of "Cancer Clinical Trials Recruitment and Retention Tools for Participant Engagement" under a total small business set-aside solicitation. The original solicitation, PHS-2020-1, sought proposals from small businesses for SBIR...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), to Lucidact Inc., a minority-owned and disadvantaged small business located in Los Angeles, CA. The $454,524 fixed-price contract is for the development of a digital tool to integrate cancer prevention within primary care, as part of the broader SBIR program objectives to stimulate technological innovation and strengthen the role of small businesses in meeting federal research needs. The contract was awarded on August 31, 2023, with a period of performance through November 30, 2024.

Generated 8/30/24, 7:15 PM